Literature DB >> 31858557

Circular RNA TTBK2 promotes the development of human glioma cells via miR-520b/EZH2 axis.

D-H Yuan1, J Zhao, G-F Shao.   

Abstract

OBJECTIVE: Glioma is a highly malignant human disease characterized by limited response to clinical therapy. Evidence indicated that circular RNA Tau tubulin kinase 2 circular RNAs (circ-TTBK2) participated in glioma pathogenesis. However, the precise effect of circ-TTBK2 on glioma progression is needed to be highlighted.
MATERIALS AND METHODS: The levels of circ-TTBK2, microRNA-520b (miR-520b), and enhancer of zeste homologue 2 (EZH2) were detected via quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) or Western blot. 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay was performed to determine cell proliferation in vitro. Besides, a flow cytometry assay was conducted to examine apoptosis of A172 and U251 cells. Cell invasion was identified using the transwell assay. Moreover, Dual-Luciferase reporter assay was used to confirm the interaction between miR-520b and circ-TTBK2 or EZH2. The role of circ-TTBK2 in glioma progression was exposed using xenograft tumor experiments.
RESULTS: The levels of circ-TTBK2 and EZH2 were markedly augmented, whereas miR-520b expression level was notably reduced in glioma tissues and cell lines. Either circ-TTBK2 or EZH2 detection could clearly facilitate cell apoptosis and block proliferation and invasion in A172 and U251 cells, while the effect of circ-TTBK2 or EZH2 deficiency was reverted by co-transfecting with miR-520 inhibitor. Moreover, circ-TTBK2 exerted its roles via miR-520b/EZH2 axis in glioma cells, and the knockdown of circ-TTBK2 could hinder the progression of glioma.
CONCLUSIONS: Circ-TTBK2/miR-520b/EZH2 axis modulated cell proliferation, apoptosis, and invasion in glioma cell lines, and might serve as potential targets for glioma diagnosis and therapy.

Entities:  

Year:  2019        PMID: 31858557     DOI: 10.26355/eurrev_201912_19792

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  5 in total

Review 1.  Non-coding RNAs in ferroptotic cancer cell death pathway: meet the new masters.

Authors:  Mehdi Rabiee Valashedi; Chia Bamshad; Nima Najafi-Ghalehlou; Amirsadegh Nikoo; Kazuo Tomita; Yoshikazu Kuwahara; Tomoaki Sato; Amaneh Mohammadi Roushandeh; Mehryar Habibi Roudkenar
Journal:  Hum Cell       Date:  2022-04-12       Impact factor: 4.174

2.  CircTTBK2 Contributes to the Progression of Glioma Through Regulating miR-145-5p/CPEB4 Axis.

Authors:  Yan Liu; Ruilong Li; Xuan Wang; Weidong Yang
Journal:  Cancer Manag Res       Date:  2020-09-08       Impact factor: 3.989

3.  Deregulated molecules and pathways in the predisposition and dissemination of breast cancer cells to bone.

Authors:  Laijian Sui; Andrew Sanders; Wen G Jiang; Lin Ye
Journal:  Comput Struct Biotechnol J       Date:  2022-05-30       Impact factor: 6.155

Review 4.  The long and short non-coding RNAs modulating EZH2 signaling in cancer.

Authors:  Sepideh Mirzaei; Mohammad Hossein Gholami; Kiavash Hushmandi; Farid Hashemi; Amirhossein Zabolian; Israel Canadas; Ali Zarrabi; Noushin Nabavi; Amir Reza Aref; Francesco Crea; Yuzhuo Wang; Milad Ashrafizadeh; Alan Prem Kumar
Journal:  J Hematol Oncol       Date:  2022-03-02       Impact factor: 17.388

Review 5.  Non-Coding RNAs and Brain Tumors: Insights Into Their Roles in Apoptosis.

Authors:  Omid Reza Tamtaji; Maryam Derakhshan; Fatemeh Zahra Rashidi Noshabad; Javad Razaviyan; Razie Hadavi; Hamed Jafarpour; Ameneh Jafari; Ali Rajabi; Michael R Hamblin; Mahmood Khaksary Mahabady; Mohammad Taghizadieh; Hamed Mirzaei
Journal:  Front Cell Dev Biol       Date:  2022-01-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.